Many CF therapeutics in the pipeline target CFTR with the goal of restoring channel function, but recent findings suggest that the bacterial virulence factor sphingomyelinase (SMase) can diminish CFTR activity in the Xenopus oocyte expression system and Calu-3 cells2–4. The gene discussed is CFTR; the disease is cystic fibrosis.